Delivery Order SPE2DB24D9144-SPE2DB24FCMMF

Award Date 9/25/24
Potential Completion Date 10/17/24
Potential Value $40K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $56,012.64, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Keytruda 100 mg/4 ml vials, with an ultimate completion date of August 19, 2024. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up...
This federal contract award, valued at $81,895.60, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of 4,567,379,133 units of Keytruda 100 mg/4 mL vial (4 mL). This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group Inc. with the DLA under the SPE2DB program,...
This federal contract award, valued at $41,020.75, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Keytruda 100 mg/4 ml vial 4 ml, a specialized oncology medication. The contract is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small...
This federal contract award, valued at $89,292.48, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Keytruda, a specialty oncology medication, with an ultimate completion date of April 18, 2022. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $81,895.60 firm fixed-price delivery order is for the supply of Keytruda 100 mg/4 ml vials, with an ultimate completion date of April 24, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue...
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $120,327.60 firm fixed-price delivery order contract is for the supply of Keytruda 100 mg/4 ml vials. The contract has an ultimate completion date of December 30, 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $121,887.13 firm fixed-price delivery order is for the supply of Keytruda 100 mg/4 ml vials. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a...
This federal contract award, valued at $16,057.14, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Keytruda 100 mg/4 ml vial, with an ultimate completion date of November 5, 2024. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
This federal contract award, with a ceiling value of $98,449.80, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a delivery order under the DLA's SPE2DB program, which is a $499,999,999 Indefinite Delivery Contract (IDC) valid through November 2026. The contract is for the supply of Keytruda 100 mg/4 ml vials, a specialized oncology medication. DMS...
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $40,109.20, is a firm fixed-price delivery order for Keytruda 100 mg/4 ml vials. This order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, that runs through December 31,...
  • SPE2DB24D9144
    Indefinite Delivery Contract
  • SPE2DB24D9144-SPE2DB24FCMMF
    Delivery Order

This federal contract award, valued at $40,142.85, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Keytruda 100 mg/4 ml vial, a cancer treatment drug, with an ultimate completion date of October 17, 2024.

DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This single-award IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation, and the company's status as a woman-owned small business has enabled it to secure direct awards for pharmaceutical Prime Vendor programs supporting military medical facilities globally.

Generated 12/25/24, 9:21 AM